Opthea Company Overview

Opthea (ASX:OPT), (NASDAQ:OPT) is a biotechnology company focused on developing and commercializing therapies to treat eye diseases. The company's main project revolves around a novel drug candidate designed to address significant needs in the ophthalmology space, particularly targeting conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). With a strong commitment to research and innovation, Opthea aims to provide new, effective treatment options for patients suffering from eye diseases. The goal is not only to advance science in the field of ophthalmology but also to improve the quality of life for those affected by these debilitating conditions.